Lyell Agrees $80 Million Placement Ahead of CAR T Pivotal Data

Company Lyell Immunopharma Event Type Private placement ($80 million) Modality Autologous dual-target CAR T Asset Ronde-cel (CD19/CD20); LYL273 (GCC) Target CD19/CD20; GCC Disease Area Large B-cell lymphoma; colorectal cancer Summary Previously missed November 4 primary disclosure: Lyell agreed to sell about $80 million of common…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *